2322 |
FMS RELATED TYROSINE KINASE 3 |
FLT3 |
CD135 |
FLK-2 |
FLK2 |
STK1 |
136351 |
3765 |
ENSG00000122025 |
OTTHUMG00000016646 |
FL CYTOKINE RECEPTOR PRECURSOR (EC 2.7.1.112) (TYROSINE-PROTEIN KINASE RECEPTOR FLT3) (STEM CELL TYROSINE KINASE 1) (STK-1) (CD135 ANTIGEN). [SOURCE:UNIPROT/SWISSPROT;ACC:P36888] |
P36888 |
24 |
Stem cell tyrosine kinase 1 |
STK-1 |
FLT-3 |
CD_antigen=CD135 |
Fms-like tyrosine kinase 3 |
Fetal liver kinase-2 |
FL cytokine receptor |
Receptor-type tyrosine-protein kinase FLT3 |
FLT3_HUMAN |
PA28181 |
T74312 |
fms related receptor tyrosine kinase 3 |
Human Readable Name | DRUGGABLE GENOME |
Target Class | Receptors |
Target Subclass | EC:2.7.10.1 |
Target Subclass | KInase |
Target Main Class | Receptors |
Transmembrane Helix Count | 2 |
Target Subclass | PDGFR |
Interpro Short Name | Ser-Thr/Tyr_kinase_cat_dom |
Interpro Type | Domain |
Human Readable Name | KINASE |
Uniprot Evidence | 1: Evidence at protein level |
Interpro Acc | IPR001245 |
Interpro Name | Serine-threonine/tyrosine-protein kinase catalytic domain |
Uniprot Status | Swiss-Prot |
CancerCommons Reported Gene Name | KIT |
CancerCommons Reported Gene Name | Receptor tyrosine kinases KIT, CSF1R, and FLT3 |
Gene Biotype | PROTEIN_CODING |
KINASE |
TYROSINE KINASE |
DRUG RESISTANCE |
DRUGGABLE GENOME |
CLINICALLY ACTIONABLE |
inhibitor (inhibitory) |
Indication/Tumor Type | acute myeloid leukemia |
Response Type | predicted – sensitive |
Approval Status | Phase Ib/II |
inhibitor (inhibitory) |
Trial Name | AC-220 |
Novel drug target | Established target |
Indication/Tumor Type | Advanced Solid Tumor |
inhibitor (inhibitory) |
Novel drug target | Established target |
Trial Name | lestaurtinib , CEP-701 |
Clinical Status | case report |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Approval Status | Phase III |
Response Type | resistant |
combination therapy | Azacitidine + Midostaurin |
inhibitor (inhibitory) |
Indication/Tumor Type | acute myeloid leukemia |
Response Type | sensitive |
Approval Status | Phase II |
inhibitor (inhibitory) |
Indication/Tumor Type | acute myeloid leukemia |
Response Type | sensitive |
Approval Status | Preclinical - Patient cell culture |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase receptor FLT3 inhibitor |
Direct Interaction | yes |
Indication/Tumor Type | acute myeloid leukemia |
inhibitor (inhibitory) |
Reported Cancer Type | Prostate |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | resistant |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase receptor FLT3 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Novel drug target | Established target |
Trial Name | tandutinib, MLN-518 |
Mechanism of Interaction | Tyrosine-protein kinase receptor FLT3 inhibitor |
inhibitor (inhibitory) |
Notes | |
Trial Name | Sutent |
Novel drug target | Established target |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Tyrosine-protein kinase receptor FLT3 inhibitor |
Notes |
n/a |
combination therapy | Enasidenib + Quizartinib |
Indication/Tumor Type | acute myeloid leukemia |
Response Type | predicted – sensitive |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase receptor FLT3 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase receptor FLT3 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase receptor FLT3 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Indication/Tumor Type | acute myeloid leukemia |
Response Type | sensitive |
Approval Status | Preclinical - Cell line xenograft |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Notes | |
Novel drug target | Established target |
Trial Name | Nexavar |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase receptor FLT3 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase receptor FLT3 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase receptor FLT3 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Tyrosine-protein kinase receptor FLT3 inhibitor |
inhibitor (inhibitory) |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | predicted – sensitive |
Approval Status | Preclinical |
inhibitor (inhibitory) |
Novel drug target | Established target |
Trial Name | ENMD-2076 |
Indication/Tumor Type | acute myeloid leukemia |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Tyrosine-protein kinase receptor FLT3 inhibitor |
n/a |
Trial Name | 4SC-203 |
Novel drug target | Established target |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Tyrosine-protein kinase receptor FLT3 inhibitor |
inhibitor (inhibitory) |
combination therapy | Azacitidine + Midostaurin |
Indication/Tumor Type | acute myeloid leukemia |
Response Type | sensitive |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase receptor FLT3 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase receptor FLT3 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase receptor FLT3 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase receptor FLT3 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase receptor FLT3 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase receptor FLT3 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase receptor FLT3 inhibitor |
Direct Interaction | yes |
Trial Name | ABT-869, Linifanib |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase receptor FLT3 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Tyrosine-protein kinase receptor FLT3 inhibitor |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
Notes |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase receptor FLT3 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase receptor FLT3 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
FLT3 | Ensembl Gene Name |
Gene Biotype | PROTEIN_CODING |
FLT3 | Display Id |
FL CYTOKINE RECEPTOR PRECURSOR (EC 2.7.1.112) (TYROSINE-PROTEIN KINASE RECEPTOR FLT3) (STEM CELL TYROSINE KINASE 1) (STK-1) (CD135 ANTIGEN). [SOURCE:UNIPROT/SWISSPROT;ACC:P36888] | Description |
ENSG00000122025 | Ensembl Gene Id |
Human Readable Name | DRUGGABLE GENOME |
DRUGGABLE GENOME |
FLT3 | Gene Symbol |
Target Class | Receptors |
Target Subclass | EC:2.7.10.1 |
ENSG00000122025 | Ensembl Gene Id |
2322 | Entrez Gene Id |
FLT3 | Gene Symbol |
Target Subclass | KInase |
Target Main Class | Receptors |
Transmembrane Helix Count | 2 |
ENSG00000122025 | Ensembl Gene Id |
FLT3_HUMAN | Uniprot Id |
FLT3 | Uniprot Gene Name |
Interpro Short Name | Ser-Thr/Tyr_kinase_cat_dom |
Interpro Type | Domain |
Human Readable Name | KINASE |
KINASE, DRUGGABLE GENOME |
2322 | Entrez Gene ID |
CancerCommons Reported Gene Name | KIT |
CancerCommons Reported Gene Name | Receptor tyrosine kinases KIT, CSF1R, and FLT3 |
2322 | CKB Entrez Id |
FLT3 | CKB Gene Synonym |
CD135 | CKB Gene Synonym |
PA28181 | PharmGKB ID |
2322 | Entrez Gene ID |
24 | CIViC Gene ID |
DRUG RESISTANCE, CLINICALLY ACTIONABLE |
2322 | Entrez Gene Id |
FLT3 | MyCancerGenome Gene Symbol |
FLT3 | MyCancerGenome Reported Gene Name |
ENSG00000122025 | Gene Symbol |
FLT3 | Ensembl Id |
DRUGGABLE GENOME |
FLT-3 | Gene Symbol |
FLT3 | Gene Symbol |
STK-1 | UNIPROT |
FLK2 | GENE_SYMBOL |
STK1 | GENE_SYMBOL |
2322 | OncoKB Entrez Id |
STK1 | OncoKB Gene Synonym |
FLK-2 | OncoKB Gene Synonym |
CD135 | GO Gene Synonym |
FLK2 | GO Gene Synonym |
STK1 | GO Gene Synonym |
TYROSINE KINASE |
FLT3 | Gene Symbol |
CLINICALLY ACTIONABLE |
2322 | Gene ID |
CD135 | dGene Synonym |
FLK-2 | dGene Synonym |
KINASE, TYROSINE KINASE |
FLT-3 | TTD Gene Abbreviation |
T74312 | TTD Target ID |
Receptor-type tyrosine-protein kinase FLT3 | Gene Name |
P36888 | UniProt ID |
KINASE |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |
DRUG RESISTANCE |